Beverly Hills, CA (PRWEB) May 30, 2014
The American College of Cardiology recently convened its 63rd meeting to discuss the latest breakthroughs in cardiovascular medicine. Topping the list of findings were a new blood test that can accurately predict heart attacks, a new cholesterol drug with fewer side effects, and an old drug that has been repurposed to treat inflammation of the sac around the heart.
“All of these are exciting results,” said Dr. Bereliani, a board-certified Beverly Hills cardiologist. “When patients come to the emergency room with symptoms of a potential heart attack, this new test will make it faster and easier for doctors to determine if they are truly in danger.”
Almost 720,000 Americans suffer from a heart attack each year. While current technology takes around six hours to determine whether or not a patient is in danger, this new blood test would substantially speed up the process.
Breakthrough Cholesterol Treatment
While still in the trial phase, PCSK9 inhibitors are showing enormous potential in lowering LDL cholesterol.
“What PCSK9 inhibitors offer,” said Dr. Bereliani, “is a way around statin intolerance, which may prevent patients who need this medication from taking it. So far the trials suggest that this treatment offers significant lowering of LDL cholesterol without the same potential for side effects as our current treatment.”
Patients with statin intolerance often experience symptoms such as:
Treatment for Acute Pericarditis
Acute pericarditis is a condition in which the sac around the heart becomes inflamed. When this happens fluid can accumulate and obstruct the flow of blood into the heart.
“This new treatment for acute pericarditis uses an old drug that is also effective in treating gout,” said Dr. Bereliani. “The new data shows that it is also useful in treating and preventing the recurrence of acute pericarditis.”
About Dr. Bereliani
Arash Bereliani, MD, FACC, is a Beverly Hills cardiologist with board certification in cardiovascular diseases, cardiac computed tomography, nuclear cardiology, and internal medicine. Dr. Bereliani currently serves as a cardiologist on staff in the Division of Cardiology at the world-renowned Cedars-Sinai Heart Institute. He is also a clinical instructor at UCLA’s David Geffen School of Medicine. Dr. Bereliani’s academic duties involve teaching as well as conducting original research on nuclear cardiology and cardiac imaging. His areas of interest include cardiac imaging, cardiac diseases, preventative cardiology, and integrative cardiology.
To learn more about Dr. Bereliani, visit his website http://www.arashbereliani.com.